Результаты поиска

Acute portal vein thrombosis in a 59-year-old male with JAK2 V617F mutation.

Portal vein thrombosis is an uncommon finding that typically arises in the context of cirrhosis. In the acute setting, it may present with abdominal pain, portal hypertension, ascites, gastrointestinal bleeding, or mesenteric ischemia. Local risk factors that predispose its formation include: cirrhosis, hepatocellular carcinoma, pancreatitis, and intraabdominal infection. Systemic factors, including hypercoagulable states and sepsis, also pose an increased risk. JAK2 V617F positive myeloproliferative disorders are associated with systemic prothrombotic states and are a less frequently identifi

Совпадение в полном тексте источника
… III deficiency; 8 in Antiphospholipid syndrome [3] Myeloproliferative disorders (PCV, ET) | JAK2 V617F [2] , [3] , [7] | 30%-40% [2] , [3] | Odds ratio: 3.0 [10] Few cases of PVT in the presence of JAK2 V617F mutation have been published in the literature. … Though family history was positive for factor V Leiden, testing for inherited or acquired thrombophilia including factor V Leiden, protein C, S, antithrombin III (ATIII), and prothrombin (G20210A) mutations yielded negative results. …

Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins, and clotting factors for transfusion support in patients with hematologic disease.

Hematologic diseases include a broad range of acquired and congenital disorders, many of which affect plasma proteins that control hemostasis and immune responses. Therapeutic interventions for these disorders include transfusion of plasma, cryoprecipitate, immunoglobulins, or convalescent plasma-containing therapeutic antibodies from patients recovering from infectious diseases, as well as concentrated pro- or anticoagulant factors. This review will focus on recent advances in the uses of plasma and its derivatives for patients with acquired and congenital hematologic disorders.

Совпадение в полном тексте источника
… Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Cooperative study group. Blood. 1990;75(1):33–39. 150. Schwartz RS, Bauer KA, Rosenberg RD, et al. … Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The antithrombin III study group. Am J Med. 1989;87(3b):53s–60s. doi: 10.1016/0002-9343(89)80533-9. 151. Thrombate III, prescribing information. …

Hemostasis at the edge between physiology and cancer.

Hemostasis lies at the edge between physiology and cancer, where the coagulation cascade-initiated by tissue factor, thrombin generation, and fibrin deposition-shifts from vascular repair to tumor promotion. The interplay between coagulation and cancer is now recognized as a two-way street, with tumor cells activating the clotting system and coagulation components feeding back to promote malignancy. Tumor cells not only foster proliferation and invasion by overexpressing tissue factor and activating Protease-Activated Receptors (PAR1/PAR2) signalling, but they also induce endothelial cells and

Hematology

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… III, plasminogen. … Most common hereditary form of thrombophilia (3–4% general population) THROMBOPHILIC MUTATIONS —antithrombin III, homozygous factor V Leiden > protein S, protein C > heterozygous factor V Leiden > prothrombin gene mutation in terms of risk of thrombosis Investigations BASIC labs —CBCD, PT, INR, …

Hematology

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… III, plasminogen. … Most common hereditary form of thrombophilia (3–4% general population) THROMBOPHILIC MUTATIONS —antithrombin III, homozygous factor V Leiden >protein S, protein C > heterozygous factor V Leiden in terms of risk of clots Investigations Basic labs —CBCD, PT, INR, activated protein C resistance, factor …

Приобретение гепариновых антикоагулянтов, связанных с множественной миеломой: three доклады и обзор литературы.

Множественная миелома (ММ) часто связана с аномалиями коагуляции, которые могут проявляться либо в тромботических, либо в геморрагических осложнениях. Среди них приобщившиеся гепаринноподобные антикоагуланты (HLA), приводящие к крайнему увеличению тромбинного времени (TT) и спонтанному кровотечению, являются крайне редкими. Раннее признание и надлежащее вмешательство имеют решающее значение для терпеливых результатов. Представляемая информация: Three (больные)two мужчины и мужчины one женщины в возрасте 56–63 ) с подтвержденным MM, спонтанным кровотечением: уральное мукосальное кровотечение, ж

Thrombotic risk in hepatitis C: Interplay between hepatic dysfunction, viral-driven inflammation, and cardiovascular consequences.

Hepatitis C virus (HCV) infection, traditionally regarded as a hepatotropic disease, is increasingly recognized as a systemic condition with significant thrombotic implications. Chronic HCV induces a persistent proinflammatory and prothrombotic state that substantially elevates the risk of both venous and arterial events. Mechanistically, HCV drives endothelial dysfunction, enhances platelet activation, disrupts coagulation and fibrinolytic balance, and promotes immune-mediated vascular injury through cryoglobulinemia and chronic systemic inflammation. Clinical manifestations range from portal

Совпадение в полном тексте источника
… Additionally, the prothrombotic state often observed in chronic liver disease includes a reduction in natural anticoagulants - such as antithrombin III, protein C, and protein S - alongside elevated levels of procoagulant factors, including factor VIII and von Willebrand factor. … Despite reduced antithrombin III levels in cirrhosis, low-molecular-weight heparin (LMWH) remains the preferred agent[ 55 ]. Direct oral anticoagulants (DOACs) are effective and may be superior to warfarin for treating PVT in compensated cirrhosis[ 56 ]. …

Management of venous thromboembolism in patients with cancer: role of dalteparin.

Cancer is a major risk factor for the development of venous thromboembolism (VTE). Conventional anticoagulant therapy with a vitamin K antagonist is more problematic in cancer patients due to an increased risk of recurrent VTE, and an increased risk of anticoagulant-related bleeding. In recent years, there has been a shift toward treating cancer patients with VTE with extended duration dalteparin. Dalteparin, a low-molecular-weight heparin, has been shown to be more effective, and as safe as conventional anticoagulant therapy, in cancer patients with VTE. This paper will (a) review the relatio

Эндоваскулярная тромбектомия у молодой пациентки с дефектом септальной системы: отчет по делу.

Крупноразмерный окклюз (LVO) у молодого пациента в возрасте до 30 лет является весьма редким явлением. При приближении к симптомам, похожим на инсульт, в молодом поколении, инсульт имитирует такие симптомы, как эпилепсия, хроническая субдуральная гематома, сжатие спинного мозга из-за грызуна диска или аутоиммунная нейропатия, как синдром Гильен-Барре или множественный склероз, безусловно, являются серьезным препятствием на пути быстрого диагностики. Такое состояние, вероятно, усугубит трудности с точным диагностикой и замедлит лечение инсульта в сочетании с редкостью инсультов у молодых людей.

Смертельная диспропорция фусариоза во время вводного терапия для взрослой острой лимфоболической лейкемии у пациента с приорной множественной миеломой.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Primary Thromboprophylaxis in Patients with Malignancies: Daily Practice Recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO), the Society of Thrombosis and Hemostasis Research (GTH), and the Austrian Society of Hematology and Oncology (ÖGHO).

Patients with cancer, both hematologic and solid malignancies, are at increased risk for thrombosis and thromboembolism. In addition to general risk factors such as immobility and major surgery, shared by non-cancer patients, cancer patients are exposed to specific thrombotic risk factors. These include, among other factors, cancer-induced hypercoagulation, and chemotherapy-mediated endothelial dysfunction as well as tumor-cell-derived microparticles. After an episode of thrombosis in a cancer patient, secondary thromboprophylaxis to prevent recurrent thromboembolism has long been established

Совпадение в полном тексте источника
… At the same time, liver cirrhosis is currently considered a prothrombotic condition due to increased factor VIII and von Willebrand factor and decreased antithrombin III and protein C levels [ 81 , 82 ], which adds to the already increased VTE risk in cancer patients. …

Prognostic value of circulating markers of neutrophil activation, neutrophil extracellular traps, coagulation and fibrinolysis in patients with terminal cancer.

Predicting survival accurately in patients with advanced cancer is important in guiding interventions and planning future care. Objective tools are therefore needed. Blood biomarkers are appealing due to their rapid measurement and objective nature. Thrombosis is a common complication in cancer. Recent data indicate that tumor-induced neutrophil extracellular traps (NETs) are pro-thrombotic. We therefore performed a comprehensive investigation of circulating markers of neutrophil activation, NET formation, coagulation and fibrinolysis in 106 patients with terminal cancer. We found that neutrop

Совпадение в полном тексте источника
… Haemostatic changes; plasma levels of alpha2-antiplasmin-plasmin complex and thrombin-antithrombin III complex in female breast cancer. Tumori. 1998;84:364–367. doi: 10.1177/030089169808400310. 56. Kohli M, Fink LM, Spencer HJ, Zent CS. …

Clinical effects of tranexamic acid on bleeding tendency due to fibrinolytic activation of AL amyloidosis.

We report a case where tranexamic acid, which is an antifibrinolytic agent, was used to effectively treat bleeding tendency in a patient with immunoglobulin light chain (AL) amyloidosis. A male patient in his 80s without a history of bleeding disorders was admitted to our hospital for the examination of bleeding tendency and was diagnosed with a bleeding disorder due to AL amyloidosis. Blood tests revealed elevated plasmin-α2-plasmin inhibitor complex levels, suggesting fibrinolytic activation. Managing the bleeding was difficult; however, we suspected fibrinolytic activation associated with A

The burden and predictors of venous thromboembolic diseases in patients with multiple primary malignancies.

BackgroundVenous thromboembolism (VTE) represents a considerable burden on cancer patients' survival and quality of life, but this burden varies based on the patient's baseline characteristics and cancer-related factors. Although solid evidence on the predictors and effect of VTE in cancer patients exists.AimTo evaluate VTE rate, morbidity, and mortality to develop parameters that could predict VTEs and their associated mortality in patients with multiple primary malignancies (MPMs).Method and resultsThis was a retrospective cohort study that took place at King Abdulaziz Medical City, Riyadh,

Совпадение в полном тексте источника
… To emphasize, although this was only proven in pancreatic cancer, antithrombin III, heparin cofactor II, protein C and S, and thrombomodulin levels decline as the disease progresses. …

The Role of Injectables in the Treatment and Prevention of Cancer-Associated Thrombosis.

Cancer-associated thrombosis (CAT) is a leading cause of death among patients with cancer. CAT can manifest itself as venous thromboembolism (VTE), in the form of deep vein thrombosis or pulmonary embolism, or arterial thromboembolism. The pathophysiology of CAT is complex and depends on cancer-, patient-, treatment- and biomarkers-related factors. Treatment of VTE in patients with cancer is complex and includes three major classes of anticoagulant agents: heparin and its derivatives, e.g., low molecular weight heparins, direct oral anticoagulants (DOACs), and vitamin K inhibitors. Given the t

Совпадение в полном тексте источника
… UFH is a mixture of glycosaminoglycans that bind to antithrombin III (AT-III) via a unique pentasaccharide sequence. Such binding enhances antithrombin’s inhibition mainly of factor Xa and factor IIa (thrombin) coagulation factors. UFH also binds cells and other plasma proteins. …

A year in pharmacology: new drugs approved by the US food and drug administration in 2025.

The US Food and Drug Administration approved 45 new drugs and 4 new cellular and gene therapy products in 2025, that is, a total of 49 new medical therapies. Oncology, hematology/immunotherapy, and cardiovascular/respiratory drugs remain most frequent. Among oncology drugs, there is a trend for targeting ever smaller subtypes of malignancies and/or rarer malignancies. Trends over the past 6 years include steady levels of first-in-indication (about 10%), first-in-class (about 38%), and next-in-class (about 51%) approvals. Along with a large share of approvals in orphan indications (> 50%), fast

RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies.

RNA interference (RNAi) provides researchers with a versatile means to modulate target gene expression. The major forms of RNAi molecules, genome-derived microRNAs (miRNAs) and exogenous small interfering RNAs (siRNAs), converge into RNA-induced silencing complexes to achieve posttranscriptional gene regulation. RNAi has proven to be an adaptable and powerful therapeutic strategy where advancements in chemistry and pharmaceutics continue to bring RNAi-based drugs into the clinic. With four siRNA medications already approved by the US Food and Drug Administration (FDA), several RNAi-based thera

Shortage of plasma-derived medicinal products: what is next? narrative literature review on its causes and counteracting policies in Italy.

Introduction: This paper describes the peculiarities of the plasma-derived medicinal product (PDMP) market and illustrates the results of a review of the literature on policies aimed at counteracting the shortage of PDMPs. Characteristics of PDMPs: Plasma is primarily used for the industrial production of blood products (80%). The demand for PDMPs, particularly immunoglobulins (IGs), is increasing. However, the production of PDMPs is complex, long (7-12 months), and expensive, accounting, according to US estimates, for 57% of the total costs of PDMPs compared to 14% for small molecules. PDMP m

Совпадение в полном тексте источника
… ➢ Antithrombin III, a drug used to treat congenital or acquired antithrombin III deficiencies. ➢ Prothrombin complex concentrate is used for the treatment and prophylaxis of bleeding episodes. …

Abstract

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

CD200 является мощным новым фактором роста в Мультимиломе, зависящим от сигнала рецептора IGF1.

CD200 — это иммунный контрольно-пропускной пункт, безошибочно выраженный в 70% недавно диагностированных пациентов с множественной миеломой (ММ) и связанный с плохим исходом. Выражение CD200 клетками опухоли препятствует иммунной реакции через взаимодействие с CD200R и участвует в устойчивости к иммунной терапии. Однако его роль в опухоли остается слабой. В этом исследовании мы показываем, что клетки MM, перевыражающие CD200, представляют собой значительное пролиферативное преимущество в свободных культурных сыворотках, средних и клоногенных анализах. Преимущество роста клеток, опосредованное